Journal of Gastrointestinal & Digestive System
Open Access

Abstract

Serum derived bovine immunoglobulin was introduced as a medical food in the U.S. in 2013. Since then it has been studied in over 800 patients with a variety of gastrointestinal illnesses including diarrhea predominant irritable bowel syndrome (IBS-D), ulcerative colitis, Crohn�s disease, pouchitis, C. difficile colitis and chronic mesenteric ischemia. Its effectiveness in these diverse disease entities is related to the ability of SBI to bind intraluminal pro-inflammatory mediators including enterotoxins, pro-inflammatory cytokines and bacterial degradation products, thereby, preventing the loss of intercellular tight junction proteins. By maintaining tight junction, integrity, dendritic antigenic stimulation in the mucosa is reduced, resulting in inhibition of the inflammatory cascade. This presentation will review the US FDA category of medical foods, the proposed mechanism of action SBI and published clinical data.

Biography

Larry I Good has been a practicing Gastroenterologist since 1978. He completed his Graduation at Colgate University in 1969; MD at Medical University of South Carolina in Charleston, SC in 1973 and; Medical Residency from 1973-76. He was Chief Medical Resident in 1976. He completed his fellowship trained in Gastroenterology from 1976-78. He served as the Director of Liver Diseases at Nassau County Medical Center and was for many years Chief in Division of Gastroenterology, Department of Medicine at South Nassau Communities Hospital. He is an Assistant Clinical Professor of Medicine at SUNY Stony Brook. He has given hundreds of lectures in his field and has authored numerous papers and abstracts. Recently, he presented the ACG Theater lecture at American College of Gastroenterology annual meeting in Chicago, Illinois in October, 2014. He was Chief Medical Officer at Ritter Pharmaceuticals in Los Angeles, California, where he expanded his research interest in the Intestinal Microbiome. His current clinical research activities involve the microbiome, inflammatory bowel disease, irritable bowel syndrome and the application of orally administered gamma globulin to patients with acute and chronic gastro-intestinal disorders.

Email: goodpharmadevco@gmail.com